Temozolomide
- Generic Name
- Temozolomide
- Brand Names
- Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C6H6N6O2
- CAS Number
- 85622-93-1
- Unique Ingredient Identifier
- YF1K15M17Y
- Background
Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...
- Indication
Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.
- Associated Conditions
- Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome
- Associated Therapies
- -
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Immatics US, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06743126
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination with Vincristine and Temozolomide in Adolescents and Young Adults with Relapsed or Refractory Sarcomas
- First Posted Date
- 2024-11-28
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- David S Shulman, MD
- Target Recruit Count
- 63
- Registration Number
- NCT06709495
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
- Conditions
- Interventions
- First Posted Date
- 2024-10-14
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 68
- Registration Number
- NCT06639607
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 182
- Registration Number
- NCT06630260
- Locations
- 🇬🇧
Cambridge University Hospitals, Cambridge, United Kingdom
🇬🇧The Royal Marsden Hospital - Drug Development Unit, Sutton, United Kingdom
🇬🇧The Royal Marsden Hospital - Neuro-Oncology Unit, Sutton, United Kingdom
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
- Conditions
- Advanced Breast CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian CarcinomaAdvanced Pancreatic CarcinomaAdvanced Prostate CarcinomaAdvanced SarcomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8
- Interventions
- Drug: AbemaciclibProcedure: BiopsyProcedure: Biospecimen CollectionDrug: FulvestrantProcedure: Bone ScanDrug: CarboplatinDrug: OlaparibProcedure: EchocardiographyDrug: GemcitabineDrug: PemetrexedDrug: ExemestaneDrug: LetrozoleDrug: GefitinibProcedure: Multigated Acquisition ScanOther: Survey AdministrationDrug: TamoxifenDrug: TemozolomideDrug: PaclitaxelDrug: OsimertinibDrug: Pegylated Liposomal Doxorubicin Hydrochloride
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06630325
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT06625047
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Study of Senaparib in Combination With Temozolomide
- Conditions
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-12-11
- Target Recruit Count
- 18
- Registration Number
- NCT06617923
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- NovoCure GmbH
- Target Recruit Count
- 741
- Registration Number
- NCT06556563
- Locations
- 🇺🇸
University of Kentucky Medical Center, Lexington, Kentucky, United States
🇺🇸Swedish Medical Center, Seattle, Washington, United States
🇺🇸UF Health Neuromedicine, Gainesville, Florida, United States
A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Target Recruit Count
- 38
- Registration Number
- NCT06556199
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hanzhou, Zhejiang, China
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 114
- Registration Number
- NCT06541262
- Locations
- 🇺🇸
Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.